Cite
HARVARD Citation
Hagen, P. et al. (2020). Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. Leukemia & lymphoma. 61 (14), pp. 3484-3492. [Online].